Table 2.
Virological characteristics of ten post-treatment patients who presented variants of rtL229V/M/F.
| P | Gen | Drug usage | HBV DNA change | Mutation |
|---|---|---|---|---|
| 1 | B | LMV | 8.7b →NDn → 7.2s | rtL229V + rtL180M + rtM204V |
| 2 | B | LMV | 6.6b →NDn → 4.0s | rtL229V + rtM204I |
| 3* | B | LMV | UKb →NDn → 6.1s | rtL229V |
| 4* | B | ETV | 6.0b →4.3s → 3.1n | rtL229F + rtM204I |
| 5 | C | LMV | 6.3b →NDn → 4.2s | rtL229M + rtL180M + rtM204V |
| 6 | C | ETV | 6.7b →3.9s → NDn | rtL229V |
| 7 | C | ETV | 7.6b →5.1s →NDn | rtL229M |
| 8 | C | LMV | 7.0b →NDn → 7.1s | rtL229V + rtL180M + rtM204V |
| 9 | C | LdT | 5.6b →NDn → 7.9s | rtL229F + rtM204I |
| 10 | C | LMV | 5.8b →3.4n → 5.7s | rtL229M |
Note: P: patients; Gen: genotype; HBV DNA change: the increase or decrease in HBV DNA level(log10 IU/ml); b Baseline HBV DNA level: HBV DNA level detected prior to the therapy; n nadir HBV DNA level: the lowest HBV DNA level detected during the therapy; s HBV DNA level at the time point of sequencing; ND: HBV DNA not detected; UK: unknown HBV DNA level; LMV: lamivudine; LdT: telbivudine; ETV: entecavir; rt: reverse transcriptase; * patients with low therapy compliance.